KRAS and cholangiocarcinoma: In cholangiocarcinoma, FGFR2 fusions are generally mutually exclusive with alterations in MAPK pathway (KRAS, NRAS and BRAF) in baseline samples26, reflecting their roles as alternative oncogenic drivers.